Myeloid differentiation-associated autophagy drives venetoclax resistance in AML

Abstract excerpt

<title>Abstract</title> <p>Acute myeloid leukemia (AML) is a complex disease that often displays phenotypic and genotypic heterogeneity, where subclones are either refractory or frequently become resistant to treatment. Several studies have shown that the developmental stage of leukemia correlates with the response to therapies combining the BCL2 inhibitor venetoclax (Ven) with hypomethylating agents, such as aza...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Autophagy in Disease and Therapy
• Bridged Bicyclo Compounds, Heterocyclic
• Drug Resistance, Neoplasm
• Histone Deacetylase Inhibitors Research
• Leukemia, Myeloid, Acute
• Multiple Myeloma Research and Treatments
• Sulfonamides

Identifiers and source

Literature Corpus work

d9123914-a713-50a4-ad6f-7e5b46cf3609

DOI

10.21203/rs.3.rs-10617934/v1